Charted
Wednesday, Nov. 18, 2026The business of health, by the numbers
Live trackersDeal tracker $7.07B raisedFDA clearances 293 510(k)s in OctoberForm D raises $839M in 30 daysNew trials 266 Phase 2/3 in 30 days
Deals·Xodus Medical

Steris agrees to buy Xodus Medical for $2.1 billion, far beyond its recent tuck-in deals

Steris expects the maker of Pink Pad surgical positioning products to bring in about $245 million in 2026 revenue. It will fund the cash deal mainly with debt, backed by a $2 billion bridge commitment.

From Steris' Form 8-K filed Oct. 13, 2026, the company's Oct. 12 announcement (GlobeNewswire, as republished by Finviz) and as reported by Pulse 2.0, and MedTech Dive coverage published Oct. 13
Xodus Medical's mock operating room, with the company's patient-positioning pads on surgical tables.
Xodus Medical's mock operating room, with the company's patient-positioning pads on surgical tables.Courtesy of Xodus Medical
Value
$2.1B
Type
Acquisition
Target
Xodus Medical
Buyer
Steris
Sector
Medtech
Announced
Oct. 12, 2026

Over its last two fiscal years, Steris completed acquisitions worth less than $80 million combined. On Oct. 12 it agreed to pay $2.1 billion in cash for a single company: Xodus Medical, a Pennsylvania maker of products meant to make surgery safer for patients and staff.

The comparison comes from MedTech Dive, which reported that Steris completed two tuck-in deals worth about $23.4 million in the fiscal year that ended March 31 and several totaling $54.1 million the year before. Its last large purchase was $540 million for assets from BD in 2023.

Why it matters: Steris, which sells hospitals equipment and services for disinfecting and sterilizing, is buying a business built on consumables used in the operating room, a category that helped lift its latest quarter. Healthcare consumables revenue rose 9% in Steris' most recent quarter, contributing to a 7% increase in total sales to $1.5 billion, MedTech Dive reported.

Steris expects Xodus to generate about $245 million in revenue and about $135 million in adjusted earnings before interest and taxes in calendar 2026. That implies an adjusted EBIT margin of about 55%. At $2.1 billion, Steris is paying about 8.6 times that revenue and about 15.6 times that adjusted EBIT.

Steris also expects cash tax benefits from the deal with a net present value of about $300 million, which it said brings the net price to about $1.8 billion. On that basis, the multiples fall to about 7.3 times revenue and 13.3 times adjusted EBIT.

The sellers could earn as much as $150 million more if the business meets performance goals in calendar 2028, and the price can be adjusted under customary terms. According to Steris' Form 8-K, its subsidiary Steris Corporation signed the agreement Oct. 11 with Craig E. Kaforey and Mark A. Kaforey, individually and through their legacy trusts. Craig Kaforey is Xodus' chief executive.

What Xodus makes

Xodus was founded in 1993 and is based near Pittsburgh, according to Steris. Its flagship line is the Pink Pad, used to position patients on the operating table, and it also sells the See Sharp, a device for cleaning and defogging laparoscopes, MedTech Dive reported.

Dan Carestio, Steris' president and chief executive, said the portfolio "complements and expands STERIS's offering, particularly by adding consumables used in the operating room." He said Xodus has shown it can grow by double digits.

The deal marks a shift in scale for a company whose chief executive told a Morgan Stanley event in September that Steris mostly pursues tuck-in deals, with larger opportunities arising only now and then, MedTech Dive reported. Needham analysts wrote that the purchase "makes sense" because it adds high-growth, high-margin consumables, called the terms reasonable and forecast that it would lift Steris' earnings per share starting in 2027, according to the outlet.

Financing and what comes next

Steris plans to pay mainly with borrowed money. The 8-K says JPMorgan Chase Bank and Goldman Sachs Bank USA committed to a senior unsecured bridge facility of up to $2 billion.

The deal is expected to close by Dec. 31, subject to customary conditions and regulatory approvals. Either side may walk away if it has not closed by July 12, 2027, a date that can be pushed to Jan. 11, 2028, in certain circumstances.

Goldman Sachs is Steris' exclusive financial adviser and Jones Day its legal counsel. J.P. Morgan advised Xodus, with Morgan, Lewis & Bockius as legal counsel.

After closing, Steris plans to publish a revised fiscal 2027 outlook that includes Xodus, giving investors the company's first forecast with the deal built in.

Sara Montes de Oca is the Editor in Chief of Charted. She previously worked as a correspondent and producer in Washington, D.C., covering business, finance, and politics. Drafted with automated tools from the sources listed with this story and checked against them before publishing. How we report.

More Deals

More
Newsletter

Charted Daily

The day's deals, FDA decisions and policy moves, by the numbers. Free. Sign up now to get the first edition.

No spam. Unsubscribe any time.